Aytu biopharma reports fourth quarter and full-year fiscal 2021 financial results

Quarterly net revenue increased 74% sequentially to $23.5m; 138% year-over-year to $65.6m ended quarter with approximately $50m in cash, cash equivalents and restricted cash planned pivotal study for ar101 in vascular ehlers-danlos syndrome (veds) to begin in 1h22; scientific advisory board recently formed initiation of healight randomized, sham-controlled study planned near-term; recently published positive and validating data for uv-a light technology platform future revenue growth expected from newly consolidated sales force and product portfolio supported by fully integrated and expanding rxconnect patient support program management to host live conference call and webcast today at 4:30 p.m. et englewood, co / accesswire / september 27, 2021 / aytu biopharma, inc. (nasdaq:aytu), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today reported financial results for the fiscal fourth quarter and full-year ended june 30, 2021.
AYTU Ratings Summary
AYTU Quant Ranking